Join the Baloxavir Marboxil group to help and get support from people like you.
Baloxavir Marboxil News
Single-Dose Baloxavir Treatment Can Reduce Influenza Transmission
THURSDAY, April 24, 2025 – A single-dose baloxavir treatment can reduce influenza transmission from index patients to household contacts, according to a study published in the April 24 issue of the...
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved for children as young as five years of age The FDA also approved Xofluza to prevent influenza in...
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
South San Francisco, CA – November 23, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a...
Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications
South San Francisco, CA – October 17, 2019 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug...
FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
October 24, 2018 – Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older...
Further information
Related condition support groups
Influenza Prophylaxis, Influenza